{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:55:33Z","timestamp":1793850933750,"version":"4.6.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007229","name":"Bijzonder Onderzoeksfonds UGent","doi-asserted-by":"publisher","award":["44430"],"award-info":[{"award-number":["44430"]}],"id":[{"id":"10.13039\/501100007229","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BASL"},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1802154N"],"award-info":[{"award-number":["1802154N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03114-2","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:16:38Z","timestamp":1772028998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metabolic dysfunction-associated steatotic liver disease is associated with vascular dysfunction in type 1 diabetes"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4822-4113","authenticated-orcid":false,"given":"Jonathan","family":"Mertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Stoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-2210","authenticated-orcid":false,"given":"Eveline","family":"Dirinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Heuten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-3203","authenticated-orcid":false,"given":"Christophe","family":"De Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"15","key":"3114_CR1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407\u201318.","journal-title":"N Engl J Med"},{"issue":"10146","key":"3114_CR2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","volume":"392","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Sattar N, Franz\u00e9n S, Rawshani A, Hattersley AT, Svensson AM, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477\u201386.","journal-title":"Lancet"},{"key":"3114_CR3","doi-asserted-by":"crossref","unstructured":"Hallstr\u00f6m S, Wijkman MO, Ludvigsson J, Ekman P, Pfeffer MA, Wedel H et al. Risk factors, mortality trends, and cardiovascular diseases in people with type 1 diabetes and controls in Sweden: an observational cohort study. Lancet Reg Health \u2013 Europe. 2022;21.","DOI":"10.1016\/j.lanepe.2022.100469"},{"issue":"8","key":"3114_CR4","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2337\/dc20-2816","volume":"44","author":"V Harjutsalo","year":"2021","unstructured":"Harjutsalo V, Barlovic DP, Gordin D, Forsblom C, King G, Groop PH. Presence and determinants of cardiovascular disease and mortality in individuals with type 1 diabetes of long duration: the FinnDiane 50 years of diabetes study. Diabetes Care. 2021;44(8):1885\u201393.","journal-title":"Diabetes Care"},{"issue":"21","key":"3114_CR5","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","volume":"371","author":"M Lind","year":"2014","unstructured":"Lind M, Svensson AM, Kosiborod M, Gudbj\u00f6rnsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972\u201382.","journal-title":"N Engl J Med"},{"issue":"1","key":"3114_CR6","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41598-021-82398-8","volume":"11","author":"L Lind","year":"2021","unstructured":"Lind L, Sundstr\u00f6m J, \u00c4rnl\u00f6v J, Ris\u00e9rus U, Lampa E. A longitudinal study over 40 years to study the metabolic syndrome as a risk factor for cardiovascular diseases. Sci Rep. 2021;11(1):2978.","journal-title":"Sci Rep"},{"issue":"39","key":"3114_CR7","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"1 Suppl 1","key":"3114_CR8","first-page":"S207","volume":"48","author":"10. Cardiovascular disease and","year":"2025","unstructured":"10. Cardiovascular disease and. risk management: standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S207\u201338.","journal-title":"Diabetes Care"},{"issue":"6","key":"3114_CR9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.diabet.2020.09.001","volume":"46","author":"B Verg\u00e8s","year":"2020","unstructured":"Verg\u00e8s B. Cardiovascular disease in type 1 diabetes: a review of epidemiological data and underlying mechanisms. Diabetes Metab. 2020;46(6):442\u20139.","journal-title":"Diabetes Metab"},{"issue":"1","key":"3114_CR10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/EJE-14-0911","volume":"173","author":"E Donga","year":"2015","unstructured":"Donga E, Dekkers OM, Corssmit EP, Romijn JA. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol. 2015;173(1):101\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"3114_CR11","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1210\/clinem\/dgae175","volume":"110","author":"J Mertens","year":"2025","unstructured":"Mertens J, Roosens L, Braspenning R, Vandebeeck J, Francque S, De Block C. The 13\u00a0C glucose breath test accurately identifies insulin resistance in people with type 1 diabetes. J Clin Endocrinol Metab. 2025;110(2):e432\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3114_CR12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1210\/endrev\/bnae032","volume":"46","author":"M Apostolopoulou","year":"2025","unstructured":"Apostolopoulou M, Lambadiari V, Roden M, Dimitriadis GD. Insulin resistance in type 1 diabetes: pathophysiological, clinical, and therapeutic relevance. Endocr Rev. 2025;46(3):317\u201348.","journal-title":"Endocr Rev"},{"issue":"12","key":"3114_CR13","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.2337\/dc24-0475","volume":"47","author":"R Sun","year":"2024","unstructured":"Sun R, Wang J, Li M, Li J, Pan Y, Liu B, et al. Association of insulin resistance with cardiovascular disease and all-cause mortality in type 1 diabetes: systematic review and meta-analysis. Diabetes Care. 2024;47(12):2266\u201374.","journal-title":"Diabetes Care"},{"issue":"1","key":"3114_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41387-019-0101-1","volume":"9","author":"J Khawandanah","year":"2019","unstructured":"Khawandanah J. Double or hybrid diabetes: a systematic review on disease prevalence, characteristics and risk factors. Nutr Diabetes. 2019;9(1):33.","journal-title":"Nutr Diabetes"},{"issue":"3","key":"3114_CR15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO Clinical","year":"2024","unstructured":"EASL-EASD-EASO Clinical. Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"12","key":"3114_CR16","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1007\/s00125-024-06273-7","volume":"67","author":"A Lavens","year":"2024","unstructured":"Lavens A, De Block C, Oriot P, Crenier L, Philips JC, Vandenbroucke M, et al. Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study. Diabetologia. 2024;67(12):2678\u201390.","journal-title":"Diabetologia"},{"issue":"7","key":"3114_CR17","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.jhepr.2023.100753","volume":"5","author":"J Mertens","year":"2023","unstructured":"Mertens J, Weyler J, Dirinck E, Vonghia L, Kwanten WJ, Mortelmans L, et al. Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes. JHEP Rep. 2023;5(7):100753.","journal-title":"JHEP Rep"},{"issue":"1","key":"3114_CR18","doi-asserted-by":"crossref","first-page":"29580","DOI":"10.1038\/s41598-025-15343-8","volume":"15","author":"E Kliemank","year":"2025","unstructured":"Kliemank E, von Rauchhaupt E, Seebauer L, Roshan M, Ansmann M, Flegka V, et al. Cohort profile of the Heidelberg study on diabetes and complications HEIST-DiC. Sci Rep. 2025;15(1):29580.","journal-title":"Sci Rep"},{"issue":"2","key":"3114_CR19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","volume":"82","author":"S Driessen","year":"2025","unstructured":"Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology. 2025;82(2):487\u2013503.","journal-title":"Hepatology"},{"issue":"7","key":"3114_CR20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393(7):683\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"3114_CR21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12933-025-02764-y","volume":"24","author":"J Mertens","year":"2025","unstructured":"Mertens J, Weyler J, Dirinck E, Vonghia L, Kwanten WJ, Van Gaal LF, et al. Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol. 2025;24(1):230.","journal-title":"Cardiovasc Diabetol"},{"key":"3114_CR22","doi-asserted-by":"crossref","first-page":"204201882110555","DOI":"10.1177\/20420188211055557","volume":"12","author":"J Mertens","year":"2021","unstructured":"Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab. 2021;12:20420188211055557.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"3114_CR23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijcard.2016.10.040","volume":"225","author":"A Mantovani","year":"2016","unstructured":"Mantovani A, Mingolla L, Rigolon R, Pichiri I, Cavalieri V, Zoppini G, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol. 2016;225:387\u201391.","journal-title":"Int J Cardiol"},{"issue":"1","key":"3114_CR24","doi-asserted-by":"crossref","first-page":"101462","DOI":"10.1016\/j.jacadv.2024.101462","volume":"4","author":"S Erqou","year":"2025","unstructured":"Erqou S, Shahab A, Fayad FH, Haji M, Yuyun MF, Joseph J, et al. Cardiovascular risk prediction scores in type 1 diabetes: a systematic review and meta-analysis. JACC Adv. 2025;4(1):101462.","journal-title":"JACC Adv"},{"issue":"11","key":"3114_CR25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus. Circulation. 2016;133(11):1058\u201366.","journal-title":"Circulation"},{"issue":"1","key":"3114_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/cvr\/cvaa085","volume":"117","author":"Y Alexander","year":"2021","unstructured":"Alexander Y, Osto E, Schmidt-Trucks\u00e4ss A, Shechter M, Trifunovic D, Duncker DJ, et al. Endothelial function in cardiovascular medicine: a consensus paper of the European Society of cardiology working groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis. Cardiovasc Res. 2021;117(1):29\u201342.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"3114_CR27","doi-asserted-by":"crossref","first-page":"e013915","DOI":"10.1161\/JAHA.119.013915","volume":"9","author":"T Maruhashi","year":"2020","unstructured":"Maruhashi T, Kajikawa M, Kishimoto S, Hashimoto H, Takaeko Y, Yamaji T, et al. Diagnostic criteria of flow-mediated vasodilation for normal endothelial function and nitroglycerin-induced vasodilation for normal vascular smooth muscle function of the brachial artery. J Am Heart Assoc. 2020;9(2):e013915.","journal-title":"J Am Heart Assoc"},{"issue":"30","key":"3114_CR28","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1093\/eurheartj\/ehz350","volume":"40","author":"DHJ Thijssen","year":"2019","unstructured":"Thijssen DHJ, Bruno RM, van Mil A, Holder SM, Faita F, Greyling A, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019;40(30):2534\u201347.","journal-title":"Eur Heart J"},{"issue":"2","key":"3114_CR29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/0003319718787366","volume":"70","author":"P Wang","year":"2019","unstructured":"Wang P, Xu YY, Lv TT, Guan SY, Li XM, Li XP, et al. Subclinical atherosclerosis in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Angiology. 2019;70(2):141\u201359.","journal-title":"Angiology"},{"issue":"6","key":"3114_CR30","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1161\/ATVBAHA.112.300934","volume":"33","author":"T Maruhashi","year":"2013","unstructured":"Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, et al. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol. 2013;33(6):1401\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"3114_CR31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.109.864801","volume":"120","author":"J Yeboah","year":"2009","unstructured":"Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120(6):502\u20139.","journal-title":"Circulation"},{"issue":"9","key":"3114_CR32","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/HYPERTENSIONAHA.123.21318","volume":"80","author":"DW An","year":"2023","unstructured":"An DW, Hansen TW, Aparicio LS, Chori B, Huang QF, Wei FF, et al. Derivation of an outcome-driven threshold for aortic pulse wave velocity: an individual-participant meta-analysis. Hypertension. 2023;80(9):1949\u201359.","journal-title":"Hypertension"},{"issue":"19","key":"3114_CR33","doi-asserted-by":"crossref","first-page":"e017165","DOI":"10.1161\/JAHA.120.017165","volume":"9","author":"NH Tougaard","year":"2020","unstructured":"Tougaard NH, Theilade S, Winther SA, Tofte N, Ahluwalia TS, Hansen TW, et al. Carotid-femoral pulse wave velocity as a risk marker for development of complications in type 1 diabetes mellitus. J Am Heart Assoc. 2020;9(19):e017165.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"3114_CR34","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYP.0000000000000033","volume":"66","author":"RR Townsend","year":"2015","unstructured":"Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al. Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension. 2015;66(3):698\u2013722.","journal-title":"Hypertension"},{"issue":"3","key":"3114_CR35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/HJH.0b013e32834fa8b0","volume":"30","author":"LM Van Bortel","year":"2012","unstructured":"Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445\u20138.","journal-title":"J Hypertens"},{"issue":"13","key":"3114_CR36","doi-asserted-by":"crossref","first-page":"e029656","DOI":"10.1161\/JAHA.123.029656","volume":"12","author":"J Ge","year":"2023","unstructured":"Ge J, Jing F, Ji R, Tian A, Su X, Li W, et al. Age-related trends in the predictive value of carotid intima-media thickness for cardiovascular death: a prospective population-based cohort study. J Am Heart Assoc. 2023;12(13):e029656.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"3114_CR37","doi-asserted-by":"crossref","first-page":"e022922","DOI":"10.1161\/JAHA.121.022922","volume":"10","author":"JF Polak","year":"2021","unstructured":"Polak JF, Backlund JC, Budoff M, Raskin P, Bebu I, Lachin JM. Coronary artery disease events and carotid intima-media thickness in type 1 diabetes in the DCCT\/EDIC cohort. J Am Heart Assoc. 2021;10(24):e022922.","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"3114_CR38","doi-asserted-by":"crossref","first-page":"e031217","DOI":"10.1161\/JAHA.123.031217","volume":"12","author":"Y Ling","year":"2023","unstructured":"Ling Y, Wan Y, Barinas-Mitchell E, Fujiyoshi A, Cui H, Maimaiti A, et al. Varying definitions of carotid intima-media thickness and future cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2023;12(23):e031217.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"3114_CR39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"3114_CR40","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation. 2016;133(11):1058\u201366.","journal-title":"Circulation"},{"issue":"3","key":"3114_CR41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"EASL Clinical Practice","year":"2021","unstructured":"EASL Clinical Practice. Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"10","key":"3114_CR42","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104\u201312.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"24","key":"3114_CR43","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","volume":"126","author":"V Aboyans","year":"2012","unstructured":"Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890\u2013909.","journal-title":"Circulation"},{"issue":"23 Suppl 1","key":"3114_CR44","first-page":"Iii27","volume":"109","author":"J Davignon","year":"2004","unstructured":"Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):Iii27\u201332.","journal-title":"Circulation"},{"key":"3114_CR45","doi-asserted-by":"crossref","unstructured":"M\u00f8ller S, Kimer N, Hove JD, Barl\u00f8se M, Gluud LL. Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects. Eur J Prev Cardiol. 2025.","DOI":"10.1093\/eurjpc\/zwae306"},{"issue":"1","key":"3114_CR46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"3114_CR47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9149(00)01321-7","volume":"87","author":"OT Raitakari","year":"2001","unstructured":"Raitakari OT, Seale JP, Celermajer DS. Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis. Am J Cardiol. 2001;87(2):217\u20139. a8.","journal-title":"Am J Cardiol"},{"issue":"1","key":"3114_CR48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0735-1097(98)00206-X","volume":"32","author":"MR Adams","year":"1998","unstructured":"Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, et al. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol. 1998;32(1):123\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"3114_CR49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fendo.2020.00203","volume":"11","author":"E Lespagnol","year":"2020","unstructured":"Lespagnol E, Dauchet L, Pawlak-Chaouch M, Balestra C, Berthoin S, Feelisch M, et al. Early endothelial dysfunction in type 1 diabetes is accompanied by an impairment of vascular smooth muscle function: a meta-analysis. Front Endocrinol (Lausanne). 2020;11:203.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3114_CR50","doi-asserted-by":"crossref","first-page":"26805","DOI":"10.1038\/srep26805","volume":"6","author":"L Zhang","year":"2016","unstructured":"Zhang L, Guo K, Lu J, Zhao F, Yu H, Han J, et al. Nonalcoholic fatty liver disease is associated with increased carotid intima-media thickness in type 1 diabetic patients. Sci Rep. 2016;6(1):26805.","journal-title":"Sci Rep"},{"issue":"25 Suppl 2","key":"3114_CR51","first-page":"S49","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr., Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S49\u201373.","journal-title":"Circulation"},{"issue":"42","key":"3114_CR52","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. 2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378.","journal-title":"Eur Heart J"},{"issue":"4","key":"3114_CR53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1590\/1806-9282.20200695","volume":"67","author":"A Lima","year":"2021","unstructured":"Lima A, Gon\u00e7alves MF, Rocha EV, D\u2019\u00c1vila LBO, Mascarenhas AN. Ankle-brachial index and subclinical atherosclerosis in type 1 diabetes. Rev Assoc Med Bras (1992). 2021;67(4):505\u201310.","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"8","key":"3114_CR54","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2337\/dc12-0178","volume":"35","author":"NM Hanssen","year":"2012","unstructured":"Hanssen NM, Huijberts MS, Schalkwijk CG, Nijpels G, Dekker JM, Stehouwer CD. Associations between the ankle-brachial index and cardiovascular and all-cause mortality are similar in individuals without and with type 2 diabetes: nineteen-year follow-up of a population-based cohort study. Diabetes Care. 2012;35(8):1731\u20135.","journal-title":"Diabetes Care"},{"key":"3114_CR55","first-page":"204800402513259","volume":"14","author":"IL Mladenova","year":"2025","unstructured":"Mladenova IL, Tan EF, Ng JY, Sharma P. Non-alcoholic fatty liver disease (NAFLD) and its association to cardiovascular disease: a comprehensive meta-analysis. JRSM Cardiovasc Dis. 2025;14:20480040251325929.","journal-title":"JRSM Cardiovasc Dis"},{"issue":"4","key":"3114_CR56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/17474124.2025.2471871","volume":"19","author":"A Giannakodimos","year":"2025","unstructured":"Giannakodimos A, Oikonomou E, Pantelidis P, Theofilis P, Katsiki N, Goliopoulou A, et al. Arterial stiffness as a complication of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2025;19(4):413\u201326.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"3114_CR57","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702.","journal-title":"Gut"},{"issue":"1","key":"3114_CR58","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1186\/s12889-025-23883-x","volume":"25","author":"J Zhang","year":"2025","unstructured":"Zhang J, Li L, Lin L, Wu Y, Hu L, Feng Z, et al. Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD. BMC Public Health. 2025;25(1):2747.","journal-title":"BMC Public Health"},{"issue":"1","key":"3114_CR59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12933-023-01945-x","volume":"22","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Morieri ML, Palmisano L, Masulli M, Cossu E, Baroni MG, et al. Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus. Cardiovasc Diabetol. 2023;22(1):204.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"3114_CR60","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.cgh.2024.09.038","volume":"23","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Khalil SM, Villela-Nogueira CA, Mantovani A. Global epidemiology and characteristics of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes mellitus: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025;23(8):1308\u2013e1917.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"3114_CR61","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.2337\/dc20-0078","volume":"43","author":"A Tynj\u00e4l\u00e4","year":"2020","unstructured":"Tynj\u00e4l\u00e4 A, Forsblom C, Harjutsalo V, Groop PH, Gordin D. Arterial stiffness predicts mortality in individuals with type 1 diabetes. Diabetes Care. 2020;43(9):2266\u201371.","journal-title":"Diabetes Care"},{"issue":"12","key":"3114_CR62","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.2337\/dc16-2523","volume":"40","author":"JQ Purnell","year":"2017","unstructured":"Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the diabetes control and complications trial\/epidemiology of diabetes interventions and complications (DCCT\/EDIC) study. Diabetes Care. 2017;40(12):1756\u201362.","journal-title":"Diabetes Care"},{"key":"3114_CR63","doi-asserted-by":"crossref","unstructured":"Wei Y, Andersson T, Tuomi T, Nystr\u00f6m T, Carlsson S. Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality. Eur Heart J. 2025.","DOI":"10.1093\/eurheartj\/ehaf304"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03114-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03114-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03114-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:47:18Z","timestamp":1774972038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03114-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3114"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03114-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local Ethics Committee of the Antwerp University Hospital (Belgian registration number: B3002021000052) and was conducted according to the amended Declaration of Helsinki. All participants provided written informed consent prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JM has received unconditional research grants from Astra Zeneca and Boehringer-Ingelheim. HH has received unconditional research grants from Abbott, Medtronic, Biotronik, Boston Scientific, Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer-BMS; and payments or honoraria for lectures, presentations, Speaker Bureaus, manuscript writing, or educational events from Bayer, Biotronik, Bristol Myers Squibb, Daiichi Sankyo, Milestone Pharmaceuticals, Pfizer-BMS, Centrix India, CTI Germany, the European Society of Cardiology, Medscape, and Springer Healthcare Ltd. SF has been lecturer for AbbVie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera, Siemens. He has acted as consultant for AbbVie, Actelion, Aelin Therapeutics, AgomAb, Aligos Therapeutics, Allergan, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristoll-Meyers Squibb, CSL Behring, Coherus, Echosens, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Genflow Bio, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, NGM Bio, Novartis, Novo Nordisk, PRO.MED.CS, Promethera, Roche. His institution has received grants from Astellas, Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Janssens Pharmaceutica, Inventiva, Merck Sharp & Dome, Pfizer, Roche. CDB has received consulting fees and honoraria for speaking from: Abbott, A. Menarini Diagnostics, Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Company, Medtronic, Novo Nordisk, and Roche. The other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}